ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Subcutaneous adipose tissue loss as an early indicator of cancer cachexia in unresectable pancreatic cancer.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design.Cancer reports (Hoboken, N.J.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBody-composition indices beyond body mass index (BMI) are increasingly being investigated as prognostic cancer markers. In pancreatic cancer, the prognostic relevance of skeletal muscle and adipose tissue compartments remains uncertain, with studies yielding inconsistent findings. We examined whether early on-treatment changes in subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and skeletal muscle index (SMI) are associated with unresectable pancreatic cancer prognosis.
methodsThis retrospective cohort study comprised patients with unresectable pancreatic cancer who received chemotherapy between 2019 and 2024. Baseline and 3-month computed tomography (CT) scans at L3 were analyzed to quantify SAT, VAT, and SMI, calculating percent changes (Δ%). A 3-month landmark approach was applied to survival analyses. Associations with overall survival (OS) were examined using Cox models; discrimination with receiver operating characteristic curves; and survival differences using Kaplan-Meier and log-rank tests.
resultsSixty-nine patients were included (median age, 71 years; median OS, 12.0 months). Greater preservation of SAT Δ% was associated with reduced mortality risk (HR per tertile step, 0.64; 95% confidence interval, 0.44-0.94), whereas VAT and SMI changes were not significant. SAT Δ% achieved the highest AUC for classifying short- vs long-term survival (0.73) compared with VAT (0.65) and SMI (0.52). The Kaplan-Meier analysis showed significant separation between extreme SAT tertiles (p = 0.02).
conclusionEarly SAT loss was more strongly associated with poor prognosis than concurrent VAT or SMI changes. Serial assessment of SAT on routine CT may enhance early risk stratification in unresectable pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.